Snapshot from Aug 06, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Biovica receives work orders under...
Business contract expansion

Biovica receives work orders under expanded MSA

Analysis based on 11 articles · First reported Jul 07, 2026 · Last updated Jul 20, 2026

Sentiment
20
Attention
2
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The expanded agreement and subsequent work orders signal growing commercial traction for Biovica's DiviTum TKa assay, potentially increasing recurring revenue from pharma services. This positive development may boost investor confidence in Biovica's growth strategy, though the order values are modest relative to the company's overall revenue.

biotechnology pharmaceutical oncology diagnostics
Event Summary

Biovica International, a blood-based cancer monitoring company, announced on July 7, 2026, an expanded Master Services Agreement (MSA) with a leading global pharmaceutical customer to provide DiviTum TKa testing services for oncology development programs. Subsequently, on July 14, 2026, Biovica received a ninth work order under the expanded MSA for a clinical breast cancer study evaluating a next-generation CDK inhibitor, valued at approximately SEK 1.7 million. Earlier, on July 20, 2026, Biovica received the first work order under the expanded MSA for a new oncology clinical study, valued at approximately SEK 1 million. These orders demonstrate the commercial potential of DiviTum TKa as a functional biomarker in drug development and strengthen Biovica's Pharma Services business.

Key Actions
80 Biovica International received work order
Entities Involved
stock
Biovica International
Biovica is the central entity; it expanded its MSA and received work orders, validating its pharma services strategy and DiviTum TKa's commercial value.
Importance 100.0 Sentiment 30.0
per
Theis Kipling
CEO Theis Kipling is quoted commenting on the agreements, representing Biovica's leadership.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
FDA 510(k) clearance of DiviTum TKa is a prior regulatory milestone referenced in the articles.
Importance 10.0 Sentiment 0.0
cnt
United States
Biovica's CLIA-certified lab in San Diego, California, performs testing; FDA clearance of DiviTum TKa is noted.
Importance 10.0 Sentiment 0.0
per
Anders Mortensen
CFO Anders Mortensen is listed as a contact but plays no direct role in the event.
Importance 5.0 Sentiment 0.0
exch
Nasdaq First North Premier Growth Market
Biovica's shares are traded on this exchange; the event may influence trading activity.
Importance 5.0 Sentiment 0.0
priv
FNCA Sweden AB
FNCA Sweden AB is Biovica's Certified Adviser, a regulatory role not directly impacted.
Importance 5.0 Sentiment 0.0
alliance
European Union
DiviTum TKa is CE-marked in the EU, enabling commercial use there.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ European Union
United States related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.